A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512640-36-00

Acronym

M20-258

Enrollment

Registered

2024-08-05

Start date

2021-05-26

Completion date

2025-05-05

Last updated

2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Italy

None listed

Source: EU CTIS · Data processed: Feb 4, 2026